metabolase, injekcinis tirpalas
fatro s.p.a. (italija) - injekcinis tirpalas - l-carnitine hydrochloride (equivalent to l-carnitine - 500.0 mg) - 613.3 mg; thioctic acid - 20.0 mg; pyridoxine hydrochloride - 15.0 mg; cyanocobalamin - 3.0 mg; d,l-acetylmethionine - 2.0 g; l-arginine - 240.0 mg; l-ornithine hydrochloride (equivalent to l-ornithine - 120.0 mg) - 153.2 mg; l-citrulline - 120.0 mg; l-lysine hydrochloride (equivalent to l-lysine - 50.0 mg) - 62.5 mg; glycine - 150.0 mg; aspartic acid - 150.0 mg; glutamic acid - 150.0 mg; fructose - 5.0 g; sorbitol - 8.0 g; excipients up to 100.0 ml - galvijų, buivolų, arklių, kiaulių, avių, ožkų, triušių, šunų ir kačių organizmui stiprinti ir detoksikuoti, patyrus fizinį stresą ar sveikstant.
biodyl, injekcinis tirpalas
boehringer ingelheim animal health france scs (prancūzija) - injekcinis tirpalas - 100 ml tirpalo yra: natrio selenito - 0,1 g, ciankobalamino - 0,05 g, kalio aspartato hemihidrato - 1 g, magnio aspartato tetrahidrato - 1,5 g. - galvijams, avims, kiaulėms, arkliams, šunims, katėms gydyti esant medžiagų apykaitos sutrikimams ir jų profilaktikai.
quamatel
gedeon richter plc - famotidinas - plėvele dengtos tabletės - 20 mg; 40 mg - famotidine
gefitinib zentiva [gefitinib alvogen]
zentiva k.s. - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
imfinzi
astrazeneca ab - durvalumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
vimetso
krka, d.d., novo mesto - vildagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and vildagliptin
vimetso
krka, d.d., novo mesto - vildagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and vildagliptin
dipeptiven
fresenius kabi ab - n(2)-l-alanil-l-glutaminas - koncentratas infuziniam tirpalui - 200 mg/ml - alanyl glutamine
olanzapine actavis
actavis group ptc ehf. - olanzapinas - burnoje disperguojamos tabletės - 15 mg; 10 mg; 5 mg; 20 mg - olanzapine
olanzapine orion
orion corporation - olanzapinas - burnoje disperguojamos tabletės - 15 mg; 10 mg; 5 mg; 20 mg - olanzapine